- Non-inferior decreases in A1c levels;
- Significantly less hypoglycemia;
- Significant decreases in fasting blood glucose levels; and
- Significant weight advantage.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
MannKind (MNKD) is set to report 2016 second quarter results after Monday's market close.
MannKind is drowning in debt and fixed purchasing contracts but the company generates no revenue.